期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝伐单抗联合化疗治疗39例转移性结直肠癌的疗效观察

在线阅读 下载PDF
导出
摘要 目的探讨贝伐单抗联合化疗治疗转移性结直肠癌的临床疗效。方法将78例转移性结直肠癌患者随机分为观察组和对照组各39例,对照组采用FOLFOX4方案或FOLFIRI方案。观察组采用FOLFOX4方案或FOLFIRI方案联合贝伐单抗5 mg/kg静脉滴注。两组均至少治疗3个疗程以上再进行疗效评价。结果对照组有效率23.1%(9/39),临床受益率51.3%(20/39);观察组有效率38.5%(15/39),临床受益率87.2%(34/39)。经统计学处理,观察组的有效率和临床受益率均显著高于对照组(P均<0.01)。两组的毒副反应均轻微可耐受,两组各毒副反应发生情况经比较无显著性差异(P>0.05)。结论贝伐单抗联合FOLFOX4方案或FOLFIRI方案治疗转移性结直肠癌能够显著提高临床疗效,毒副反应轻微,值得推广应用。
作者 王英姿 孙德文 陈燕
机构地区 辽宁省盘锦市中心医院肿瘤内科 辽河油田总医院
出处 《中国现代药物应用》 2014年第6期138-139,共2页 Chinese Journal of Modern Drug Application
关键词 转移性结直肠癌 化疗 贝伐单抗
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献34

  • 1Kohne CH, Wils J , LorenzM , et al. Randomized phase Ⅲ study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovor-in in advauced colorectal cancer: European Organization of Research and Treatment of Cancer Gastro intestinal Group Study 40952[J]. J Clin Oncol, 2003, 21 (20) : 3721-3728.
  • 2Van Cutsem E, Hoff PM , Harper P, et al. Oral eapecitabinevs intravenous 5-fluorouracil and leueovorin : integrated efficacy data and novel analyses from two large, randomized, phase Ⅲ trials[J]. Br J Cancer, 2004, 90 (6) : 1190-1197.
  • 3Arkenau H. , Schmoll H. , Kubicka S. , et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC) : Results of the safety anti efficacy analysis[ J]. Proc Am Soc Cfin Oncol, 2005 :abstr 3507.
  • 4Popa EC. , Luo W;Hoehster H, , B,et al. A phase Ⅱ studv of ORZEL ( UFT + LV) in elderly ( = 75 years old ) patients with colorectal cancer:results of ECOG 1299 [ J]. Proe Am Soc Clin Oncol, 2005 :Abstr 3608.
  • 5Goldberg RM, Sargent DJ, Morton RF, et ai. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[ J]. J Clin Oncol ,2004,22:23-30.
  • 6Chan Ray T, Au Gordon K, Kwok Carol C, et al. Fornightly CPT-11 plus 5FU and leucovorin as first-line therapy in Chinese patients with advanced colorectal cancer (ACRC) : effieacy and toxicity data from CPT, HKI. 602, a prospective phase Ⅱ study[J]. Proc Am Soc Clin Oncol,2002, 21 :Abstr 2329.
  • 7Pitot H. C. Rowland K. M, Sargent D. J, et al. N9841 : A randomized phase Ⅲ equivalence trial of irinotecan ( CPT-11 ) versus oxaliplatin/5-flaorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5-FU [ J ]. Proc Am Soc Clin Oncol,2005, 24 :Abstr 3506.
  • 8Tournigand C, Andre T, Achille E,el al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:a randomized GERCOR study [ J ]. J Clin Oneol, 2004,22:229-237.
  • 9Rougier P, Raoul JL, Laethem V, et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA [ J]. J Clin Oncol, 2004, 22:3513-3517.
  • 10Susman E. Rash correlates with tumour response after eetuximab[J]. Lancet Oncol,2004,5:647-649.

共引文献22

中国现代药物应用
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部